# Chenny Zhang

> Chenny Zhang is a Series A investor at Cerberus Capital Management backing Life Science. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Cerberus Capital Management](https://shizune.co/investors/profile/cerberus-capital-management)
- Total investments: 4
- Last investment: Mar 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chennyzhang

Chenny Zhang is a Series A investor at Cerberus Capital Management focused on Life Science and Therapeutics. Chenny Zhang is the Board of Directors of Syntis Bio.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 50% |
| Therapeutics | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Biopharma | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Virchow Medical | Virchow Medical is a manufacturer and supplier of biopsy catchment devices. | $4.1M | Seed | Mar 24, 2026 |  |
| Ansa Biotechnologies | Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerateinnovation in biological research and engineering. | $46.4M | Series B | Oct 01, 2025 |  |
| Syntis Bio | Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M | Series A | Jul 01, 2025 |  |
| Tierra Biosciences | Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By loweringthe traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com. | $11.4M | Series A | Mar 12, 2024 |  |

4 of 4 investments shown.

## Co-investors
- [Material Impact](https://shizune.co/investors/profile/material-impact-fund) — VC Fund, 2 deals together
- [Alternative Investment Management](https://shizune.co/investors/profile/alternative-investment-management) — VC Fund, 1 deal together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 1 deal together
- [Apollo Labs](https://shizune.co/investors/profile/apollo-labs) — VC Fund, 1 deal together
- [Black Opal Ventures](https://shizune.co/investors/profile/black-opal-ventures) — VC Fund, 1 deal together
- [Blue Water Life Science Advisors](https://shizune.co/investors/profile/blue-water-life-science-advisors) — VC Fund, 1 deal together

## About Cerberus Capital Management

VC Fund · New York, United States

Cerberus Capital Management is a private investment firm that focuses on operational private equity investments. The firm manages funds and accounts for many of the world’s most respected investors.

5 contacts available at Cerberus Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Morgan Mahlock | Director | https://shizune.co/investors/profile/morgan-mahlock-a6ba |
| Amir Salek | Senior Managing Director | https://shizune.co/investors/profile/amir-salek-4e42 |
| Brett Ingersoll | President, Chief Investment Officer | https://shizune.co/investors/profile/brett-ingersoll |
| Chenny Zhang | Director | https://shizune.co/investors/profile/chenny-zhang-a2b4 |
| David Mcwilliam | Managing Director | https://shizune.co/investors/profile/david-mcwilliam |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Chenny Zhang invest in?

Chenny Zhang invests primarily in Life Science, Therapeutics and Biotechnology startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chenny Zhang last invest?

The most recent investment recorded for Chenny Zhang closed in Mar 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co